Concerns Over ACA Essential Benefits Changes Amid Trump Administration
Patient advocacy groups have raised concerns over proposed changes to the Affordable Care Act's essential health benefits by the Trump administration. The Centers for Medicare & Medicaid Services (CMS) aims to adjust rules that could impact access to services like fertility treatments, hearing aids, and critical disease screenings. Under these changes, states would be responsible for covering the financial burden of certain mandated benefits if they deem them essential.
These adjustments could limit access to vital procedures for early disease detection, as emphasized by various advocacy groups in their comments to CMS. The American Cancer Society’s Cancer Action Network expressed that while state mandates aren't explicitly prohibited, the proposal financially discourages them.
Essential health benefits define categories of care required in small group and individual market plans under the ACA. CMS proposes rescinding a 2025 guideline allowing states to avoid defraying costs of additional benefits with separate mandates. Finalizing this would mean states must cover costs for benefits mandated beyond the ACA's initial scope.
A CMS spokesperson clarified that the proposal does not eliminate specific service coverage but delineates financial responsibility when states impose additional mandates. The National Association of Insurance Commissioners noted potential financial burdens based on historic state decisions, with further complications from uncertainties over 2026 state legislative sessions and compliance requirements.
A review pause on states’ applications for updating benefits benchmarks has been announced, raising concerns about premium increases and declining enrollments due to expansive benefits. Observations from Paragon Health Institute suggest removing the provision could restore fiscal responsibility.
California Insurance Commissioner Ricardo Lara argued that additional benefits minimally impact premiums due to existing actuarial regulations. The proposal, he warned, could disrupt regulatory processes. The American Diabetes Association also voiced concerns about the affordability of essential supplies if costs escalate. The impact on costly services like fertility treatments remains uncertain, with advocates warning of potential contradictions to administrative objectives.
From the insurance industry perspective, these changes could revert to previous norms in states with longstanding mandates. States with recent benefit mandates may face challenges absorbing related costs. The Trump administration's review of broader essential benefit standards suggests potential further adjustments in the insurance landscape.